How the US and the EU supported Pfizer-Biontech, Moderna and Astrazeneca-Irbm vaccines
Purchase promises, advance money, real financing: this is how Washington and Brussels pushed Pfizer, Moderna and Astrazeneca's vaccine race
How and how much have the states funded the anti Covid vaccines from Pfizer, Moderna and Astrazeneca that should soon arrive on the market?
While the announcements on the effectiveness of drugs multiply, we take stock of those who supported (economically speaking) research and work of the pharmaceutical companies.
All the details.
PFIZER: USA PURCHASE PROMISE
This is not a real financing, but we are there. The US government has allocated, in July 2020, 1.92 billion dollars to reserve 100 million doses of the Bnt 162 vaccine, on which the American Pfizer and the German BioNTech worked in collaboration. The government reserved the right to reserve another 500 million doses later.
THE EU BOOKING
The amount is unknown, but also the EU, like the US, has reserved the Pfizer-BionTech vaccine: 200 million doses on behalf of all EU member states, reserving a purchase option up to others 100 million doses.
GERMANY FINANCES BIONTECH
A real loan has come to the German company BionTech , Pfizer collaborator. The Berlin government, Bloomberg writes, has given the German company $ 445 million.
THE ROLE OF THE EIB
Even the Bei, for this vaccine, did its part. The European Investment Bank and the immunotherapy firm BionTech have signed a € 100 million loan agreement to support the development of Bnt 162.
483 MILLION DOLLARS PER MODERN
Even the American Moderna, despite being a small company (with just over 1,000 employees), has received significant funding. Federal agency Barda has put a whopping 483 million dollars on the table to accelerate the development and production of the mRna-1273 vaccine, the main component of which is the protein S complex (viral protein Spike S), like the vaccines encoded against coronaviruses responsible for Middle Eastern respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS).
NEGOTIATIONS WITH THE EU
However, no euro has yet arrived from Europe for Moderna. The company is still in talks , despite the announcement of the very high efficacy, with the Commission for the sale of 80 doses to be distributed to all Member States. The EU, also in this case, reserves the option to purchase up to 80 million additional doses.
BARDA: 1.2 BILLION TO ASTRAZENECA
Barda, the US authority for advanced biomedical research, has also financed Astrazeneca, the company that produces and markets the vaccine developed by the University of Oxford with the collaboration of the Italian Irbm and which, according to what has been announced, has an efficacy up to 90% : $ 1.2 billion to accelerate vaccine production.
ASTRAZENECA AND THE EU CONTRACT
And it is precisely with Astrazeneca that the EU Commission signed the first purchase contract: Member States will be able to purchase 300 million doses of the vaccine , with an option to purchase an additional 100 million doses to be distributed in proportion to population.
As for the other contracts, here too the amount due in euros is top secret.
OTHER US FUNDING
Important funding has also come from Washington to Novavax: 1.6 billion dollars have gone, despite the fact that the company has never produced a vaccine. The US also financed Janssen's work with $ 456 million, Merck and Iavi with $ 38 million and Sanofi with $ 30.7 million.
CONTRACTS OF THE EU
The EU, on the other hand, in addition to Pfizer and Astrazeneca, has also signed purchase contracts with Sanofi-GSK, Janssen Pharmaceutica NV and Curevac (to which it has also granted a loan of up to 80 million euros ). The cost of the various vaccines is always top secret.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/come-usa-ed-ue-hanno-vaccinato-i-vaccini-di-pfizer-moderna-e-astrazeneca/ on Sun, 29 Nov 2020 08:08:06 +0000.